Follow

Arctic Bioscience AS – Notice of extraordinary general meeting: Marita Holstad proposed as new board member

22 October 2021 - 12:06

The Board of Directors of Arctic Bioscience AS ("the "Company") has proposed Marita Holstad as new board member and the Board of Directors of the Company calls for an extraordinary general meeting (EGM) for the election.

Marita Holstad has extensive experience from the pharmaceutical industry, and is currently Global Vice President, Commercialization Leader respiratory in GlaxoSmithKline (GSK), based in Chicago, IL. Before joining GSK, Marita Holstad has 16 years’ experience from AbbVie (previously Abbott) from management positions in Norway, UK and the US within Immunology across Rheumatology, Gastrology and Dermatology. Holstad holds an MBA degree in Strategic Leadership from the Norwegian School of Economics and Business Administration (NHH). 

"Marita Holstad has an extraordinary track-record and very relevant capabilities when it comes to developing and bringing pharmaceutical products to market, including within the field of psoriasis. Her combined strategic, operational and cross-functional experience is well aligned with Arctic Bioscience’s roadmap going forward. She will be a valuable addition to our board” says chairman Harald Nordal.

The EGM will be on 27 October 2021 at 13.00 on Microsoft Teams (link).

For further information, please contact: 

Ole Arne Eiksund
CEO of Arctic Bioscience AS
Mobile: +47 908 43 944
Email: [email protected]

Danielle Glenn
CFO of Arctic Bioscience AS
Mobile: +47 909 98 201
Email: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing pharmaceutical and nutraceutical products based on the unique properties of herring roe oil, composed of complex bioactive marine compounds, including lipids essential to maintaining cell membranes. The nutraceutical products contain lipids which contribute to the normal functioning of brain, heart and vision.

The company is developing a novel drug candidate (HRO350) for mild-to-moderate psoriasis, a large global patient population where there is substantial need for effective, convenient and cost-effective new medicines with beneficial safety profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk ingredients to other companies making dietary supplements (B2B) and as finished goods under the ROMEGA brand (B2C), with significant expansion potential all channels and regions.

To support its long-term growth strategy, Arctic Bioscience is planning a state-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and proprietary production processes will increase control of the value chain, improve margins and enable large-scale, high-quality manufacturing.

Arctic Bioscience is led by a highly competent team with significant expertise developing marine oils and extensive experience from some of the world's leading pharmaceutical, technology and financial services companies.

Provided by: Cision
Euronext Growth Oslo (Norway)
Arctic Bioscience AS
Arctic Bioscience produces unique pharmaceutical and nutraceutical products based on bioactive marine compounds. The Company is developing a novel, cost-efficient oral treatment for mild-to-moderate psoriasis – a large global market with significant unmet medical need....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More